#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16912	16S	1529	1529	100.0	16S.l15.c17.ctg.1	1971	843.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1402	1402	C	958	C,T,G	927,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31198	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3628	856.5	0	.	n	.	0	T695C	SNP	695	695	T	1067	1067	C	902	C,A	875,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31198	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3628	856.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1709	1709	A	1018	A,G	985,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31198	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3628	856.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2343	2343	C	966	C,G,A	939,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31198	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3628	856.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2969	2969	T	990	T,C	968,5	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31198	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3628	856.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2417	2417	A	1035	A	1016	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2160	folP	852	852	100.0	folP.l15.c4.ctg.1	1638	130.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1018	1020	AGC	187;184;185	A;G;C	185;184;181	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6018	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3223	185.0	1	SNP	p	S91F	0	.	.	271	273	TCC	499	501	TCC	198;199;202	T;C,A;C	194;193,1;196	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6018	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3223	185.0	1	SNP	p	D95G	0	.	.	283	285	GAC	511	513	GAC	198;195;192	G,A;A;C	191,1;187;188	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6018	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3223	185.0	1	SNP	p	D95N	0	.	.	283	285	GAC	511	513	GAC	198;195;192	G,A;A;C	191,1;187;188	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1846	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1304	140.7	0	.	p	.	0	A39T	NONSYN	115	117	GCC	444	446	ACC	180;182;180	A;C;C	168;176;173	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1846	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1304	140.7	0	.	p	.	0	R44H	NONSYN	130	132	CGC	459	461	CAC	175;172;174	C;A;C	167;166;169	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1846	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1304	140.7	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	642	644	CAC	249;247;246	C;A;C	239;231;236	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1846	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1304	140.7	1	SNP	p	G45D	0	.	.	133	135	GGC	462	464	GGC	178;176;181	G;G;C,T	173;171;176,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	970	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	917	104.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5720	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2955	192.3	1	SNP	p	D86N	0	.	.	256	258	GAC	583	585	GAC	249;249;248	G;A;C	243;236;242	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5720	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2955	192.3	1	SNP	p	S87I	0	.	.	259	261	AGT	586	588	AGT	250;253;254	A;G;T,C	244;246;240,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5720	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2955	192.3	1	SNP	p	S87R	0	.	.	259	261	AGT	586	588	AGT	250;253;254	A;G;T,C	244;246;240,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5720	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2955	192.3	1	SNP	p	S87W	0	.	.	259	261	AGT	586	588	AGT	250;253;254	A;G;T,C	244;246;240,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5720	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2955	192.3	1	SNP	p	S88P	0	.	.	262	264	TCC	589	591	TCC	254;257;257	T;C;C	244;243;244	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4614	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2665	171.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1585	1587	GGC	231;222;221	G;G;C	222;212;212	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	0	.	p	.	0	T51M	NONSYN	151	153	ACG	451	453	ATG	237;236;238	A;TGG,TG;G	225;227,1;223	.	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1231	1233	GCA	247;248;249	G;C,T;A	239;234,1;241	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1234	1236	ATC	249;245;242	A;T;C	239;234;232	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1246	1248	GTG	231;232;234	G;T,C;G	222;220,1;227	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1246	1248	GTG	231;232;234	G;T,C;G	222;220,1;227	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1750	1752	ACC	226;223;221	A;C;C	214;214;213	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1804	1806	GCG	200;199;202	G;C,G;G,C	187;167,6;190,2	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1804	1806	GCG	200;199;202	G;C,G;G,C	187;167,6;190,2	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1927	1929	GGC	152;151;147	G;G;C,T	146;147;140,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1936	1938	GGC	143;139;138	G;G;C	134;134;131	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	539	4368	penA	1749	1749	99.94	penA.l6.c30.ctg.1	2389	181.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1954	1956	CCG	115;114;114	C,G;C;G,C	106,2;107;102,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6562	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3114	209.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1630	1632	CTG	224;224;225	C;T,G;G	215;209,1;212	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2668	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1814	145.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	573	573	C	167	C,A	152,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	417	419	GGA	255;255;257	G;G;A	250;249;250	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	0	.	p	.	0	F135L	NONSYN	403	405	TTT	678	680	CTT	223;222;222	C;T;T	219;216;215	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	0	.	p	.	0	R143G	NONSYN	427	429	AGA	702	704	GGA	221;218;217	G;G;A,T,G	217;213;210,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	0	.	p	.	0	D171G	NONSYN	511	513	GAT	786	788	GGT	212;213;219	G;G;T,A	203;205;196,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	0	.	p	.	0	G189S	NONSYN	565	567	GGC	840	842	AGC	221;220;218	A;G,A;C	214;215,1;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	906	906	T	212	T	206	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	1	SNP	p	G120K	0	.	.	358	360	GGT	633	635	GGT	222;224;223	G;G;T,G	216;219;209,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	1	SNP	p	A121N	0	.	.	361	363	GCC	636	638	GCC	226;227;226	G;C,T;C	218;220,1;221	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3064	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1471	206.8	1	SNP	p	A121D	0	.	.	361	363	GCC	636	638	GCC	226;227;226	G;C,T;C	218;220,1;221	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11522	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4837	236.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1990	1992	AAT	248;247;247	A;A;T	243;242;241	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1294	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	958	133.8	1	SNP	p	V57M	1	.	.	169	171	ATG	462	464	ATG	256;254;251	A;T;G	250;248;245	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
